Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma; Zgura Anca; Oana Gabriela Trifănescu; Laurenția Nicoleta Galeș; Antonia Ruxandra Folea; Loredana Stanca; Liviu Bîlteanu; Rodica M. Anghel

doi:10.12659/MSM.941754

20 September 2023: Clinical Research

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma ^12ABCG , Zgura Anca ^1E , Oana Gabriela Trifănescu ^12A , Laurenţia Nicoleta Galeş ^12D* , Antonia Ruxandra Folea ^2CDEF , Loredana Stanca ^3B , Liviu Bîlteanu ^234ABCDEF* , Rodica M. Anghel ^1A

DOI: 10.12659/MSM.941754

Med Sci Monit 2023; 29:e941754

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Supplementary Table 5 Standard deviation, variance and the 25th, 33rd, 50th, 67th and 75th percentiles of age, weight, BMI and BSA for the patients in the study group.

Variable		Age (yrs)	Weight (kg)	Body mass index (kg/m2)	Body surface area (m2)
Std. deviation		13.29	15.94	6.04	0.21
Variance		176.52	254.10	36.51	0.04
Percentiles	25	43.25	60.00	22.76	1.63
	33	48.00	63.44	24.96	1.67
	50	58.00	70.00	26.99	1.76
	67	62.23	79.00	29.59	1.90
	75	66.75	82.00	31.65	1.92

Back to the Article

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Your Privacy